FDA orphan products development
Executive Summary
Former Center for Biologics Evaluation & Research Office of Cellular, Tissue & Gene Therapies Acting Director Phil Noguchi, MD, will leave FDA at the end of August. Noguchi has held the position of medical officer within the Office of Orphan Products Development since May (1"The Pink Sheet" May 17, 2004, In Brief)...
You may also be interested in...
FDA orphan drugs staff
Former Center for Biologics Evaluation & Research Office of Cellular, Tissue & Gene Therapies Acting Director Phil Noguchi, MD, joins Office of Orphan Products Development as medical reviewer. Joyce Frey-Vasconcells assumes acting director post at CBER's cell therapies office...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.